Near future
No Result
View All Result
27 September 2023
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+
Understand, anticipate, improve the future.
CES2023 / Coronavirus / Russia-Ukraine
Near future
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+

Understand, anticipate, improve the future.

No Result
View All Result
Medicine

Good news: mild cases of Covid-19 give long-lasting antibodies, possibly for life

New research provides high hopes for those mildly ill with Covid-19. The antibodies produced by the body are long-lasting, possibly perpetual.

May 25, 2021
Gianluca RiccioGianluca Riccio
⚪ 4 minutes
Share46Pin11Tweet29SendShare8ShareShare6

READ IN:

Months after recovery from mild cases of COVID-19, you will still have immune cells in your body, ready to produce a response to the virus.

These are the results of an antibody study by researchers at the Washington University School of Medicine in St. Louis. Such cells, this is the keystone, could persist throughout life.

Mild cases, "long" antibodies

The results, published on May 24 in the journal Nature, suggest that mild cases of COVID-19 leave long-lasting antibodies, and that subsequent bouts of the disease are likely to be rare or none at all.

Covid-19 would leave short-lasting immunity: a mistaken belief

"Last fall, there were reports that antibodies drop rapidly after falling ill with COVID-19. The mainstream media took this as a sign that immunity was not long-lasting. But this is a misinterpretation of the data. "says the senior author Ali ellebedy, PhD, associate professor of pathology and immunology, of medicine and molecular microbiology.

Antibodies
Ali Ellebedy, first author of the research on antibodies produced by mild cases of COVID-19

It is normal for antibody levels to drop after acute infection, but they do not drop to zero. They stabilize.

The article continues after the related links

To REALLY avoid new pandemics, the fur industry needs to be wiped out

There is never peace for the WHO chief: prepare for a disease more lethal than COVID

We found antibody-producing cells in people 11 months after the first symptoms. These cells will live and produce antibodies for the rest of people's lives. Strong evidence of long-lasting immunity.

Ali ellebedy

From mild cases, long-lived plasma cells

During a viral infection (specifically, SARS-CoV-2 that produces mild cases), the immune cells that produce antibodies multiply rapidly and circulate in the blood, driving antibody levels to the sky.

As the infection resolves, most of these cells die and the antibody levels in the blood drop. A small population of antibody-producing cells, called plasma cells long-lived, they migrate to the bone marrow and settle, where they continually secrete low levels of antibodies into the bloodstream to protect themselves from another encounter with the virus.

Antibodies
Plasma cells

The key? The bone marrow

The key to understanding whether COVID-19 leads to long-lasting antibody protection, Ellebedy realized, lies in the bone marrow.

To find out if those recovered from mild cases of COVID-19 harbor long-lived plasma cells that produce antibodies specifically targeted to SARS-CoV-2, Ellebedy collaborated with co-authors Iskra Pusic, Rachel Presti e Jane O'Halloran.

The team had already enrolled 77 participants who were giving blood samples at three-month intervals starting about a month after the initial infection. Most of the participants had had mild cases of COVID-19. Only six had been hospitalized.

With the help of Pusic, Ellebedy and colleagues obtained bone marrow from 18 participants seven to eight months after their initial infections. Five of them returned four months later and provided a second bone marrow sample. For comparison, the team also collected bone marrow from 11 people who had never had COVID-19.

The results of antibody research

As expected, the levels of antibodies in the blood of COVID-19 participants declined rapidly in the first few months after infection and then stabilized, with some antibodies detectable even 11 months after infection.

More: 15 of 19 bone marrow samples from people who had COVID-19 contained antibody-producing cells specifically targeted to SARS-CoV-2.

Cells were also found four months later in the five people who returned to provide a second bone marrow sample.

None of the 11 people who had never had COVID-19 had antibody-producing cells in their bone marrow.

Indefinite protection

"People with mild cases of COVID-19 clear the virus from their bodies two to three weeks after infection," says Ellebedy. "These cells don't divide. They are quiescent, found only in the bone marrow and secrete antibodies. They have done so since the infection cleared and will continue to do so indefinitely."

The well-founded hypothesis, therefore, is that infected people without symptoms or with mild symptoms will have a long, perhaps perpetual duration, immunity.

What still needs to be checked for those who have suffered a more serious infection, and especially for the vaccinated.

Tags: antibodiesCoronavirusImmunity

Latest news

  • On Mars in 26 days with the new airbrush solar sail
  • Amazon invests in Anthropic: the AI ​​war rages on
  • Smile: Drug that regrows teeth reaches clinical trials
  • Without a brake from the institutions, will AI lead to private neo-feudalism?
  • When will we become extinct? Here comes a (nice) prediction from the supercomputer
  • DNA and longevity: how 'jumping genes' could extend our lives
  • TeddyGPT arrives, the first AI teddy bear that talks and learns with children
  • Minimum wage: a step forward or a leap in the dark for Italy?
  • Solar cars could halve the need for charging
  • The crazy food of the future: from edible clouds to mussel ceramics


GPT Chat Megaeasy!

Concrete guide for those approaching this artificial intelligence tool, also designed for the school world: many examples of applications, usage indications and ready-to-use instructions for training and interrogating Chat GPT.

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

Enter the Telegram channel of Futuroprossimo, click here. Or follow us on Instagram, Facebook, Twitter, Mastodon e LinkedIn.

FacebookTwitterInstagramTelegramLinkedInMastodonPinterestTikTok

The daily tomorrow.


Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

  • Environment
  • Architecture
  • Artificial intelligence
  • Gadgets
  • concepts
  • Design
  • Medicine
  • Spazio
  • Robotica
  • Work
  • Transports
  • Energy
  • Edition Francaise
  • Deutsche Ausgabe
  • Japanese version
  • English Edition
  • Portuguese Edition
  • Read more
  • Spanish edition

Subscribe to our newsletter

  • The Editor
  • Advertising on FP
  • Privacy Policy

© 2023 Near future - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

No Result
View All Result
Understand, anticipate, improve the future.
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+